– USA, PA – Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the appointment of James J. Marino J.D., MBA, to its Board of Directors.
“I am delighted to welcome Jim to the Board of Onconova,” said Michael B. Hoffman, Chairman of the Board of Onconova. “His deep understanding of the Company and its mission combined with over two decades of experience advising the life science industry will be invaluable to Onconova. Our board looks forward to working with him.”
James J. Marino was a Partner at the global law firm of Dechert LLP for 28 years where he served as Managing Partner of the Princeton Office. During this period, he advised numerous leading life science companies in connection with financings, acquisitions and strategic alliances. Mr. Marino served as the outside counsel for Onconova from its inception through and including its initial public offering. Previously, he served on the Board of Directors of Pharmacopeia Drug Discovery, Inc. from 2000-2006 and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital. Mr. Marino was one of the co-founders of BioNJ, a trade association of biotech companies, which he has represented since 1994. He currently serves on the Board of Trustees of Wake Forest University and Wake Forest Baptist Medical Center. Mr. Marino received his B.A., J.D. and MBA from Rutgers University. Mr. Marino will join the Company’s Audit and Compensation Committees.
“I am very pleased to have the opportunity to recommit to the success of Onconova, and I look forward to assisting the Company in its efforts to address the unmet medical need of patients with myelodysplastic syndromes,” said Mr. Marino.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova’s clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company’s most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
